NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP China Pharmas » China Biopharmaceuticals Holdings  1    
found files: 18
China Biopharmaceuticals Holdings »10/05/2007 [Company watch]
China Biopharmaceuticals Holdings (CHBP) has named new officers and directors for its organization

The company has named Ms Zhang Jian as Chairwoman of the Board of Directors, Mr Shi Mingsheng as Chief Operating Officer and Mr Ding Weihua as member of the Board of Directors. The appointments come into effect from April 30, 2007. Ms Zhang Jian served as the General Manager of Suzhou Erye Pharmaceutical Company Limited (Erye) since 2003. Prior to being the General Manager for Erye, she served for more than five years as the deputy general manager of Suzhou Pharmaceutical Company. Ms Zhang has extensive background and experience in the pharmaceuticals industry having worked in various managerial positions and various aspects of the industry. She is known to be an expert in managing the growth of the company. In her new position, she will be overseeing the company's strategic growth and handle all responsibilities of the company‚Äôs operations. Mr Shi Mingsheng, named as the Chief Operating Officer of CHBP, previously served as the chairman of Suzhou Erye Pharmaceutical Company Limited since 2003. In association with Ms Zhang Jian, he built a profitable business, which currently has a joint venture with China Biopharmaceuticals. Mr Ding Weihua, elected to the Board of Directors of the company, is a veteran in the pharmaceuticals industry having worked in the field for more than 33 years. Mr Ding worked for nine years as deputy general manager and manager in sales and marketing at Erye. Prior to his positions in Erye, he worked for six years in business planning at Jiangsu Nantong Qinfen Pharmaceutical Company. ‚ÄúThese new appointments not only add depth to our management team but demonstrate our commitment to enhancing our corporate governance. The experience that all three members bring from our most successful subsidiary to date, Eyre, will have an immediate positive impact on the management and performance of China Biopharmaceuticals,‚ÄĚ said Mr Chris Peng Mao, Chief Executive Officer of China Biopharmaceuticals....   more»


China Biopharmaceuticals Holdings »17/01/2008
China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program

China Pharma Holdings, Inc. (''China Pharma'') which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced that it has retained HC International, Inc. (HCI) to initiate a proactive and targeted investor relations campaign. Matthew Hayden and Alan Sheinwald of HCI, and their collective team, will be advising the Company in all facets of public financial communications....   more»


China Biopharmaceuticals Holdings »29/01/2008 [Company watch]
China Pharma Holdings, Inc. (CPHI.OB) Receives Chinese SFDA Approval for Generic Bumetanide Injection

China Pharma Holdings, Inc. ("China Pharma") which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it has received approval from the Chinese State Food and Drug Administration (SFDA) for the production of generic Bumetanide injection which is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome by inducing dieresis...   more»


China Biopharmaceuticals Holdings »15/02/2008 [Company watch]
China Pharma Appoints Three Independent Non-Executive Directors

China Pharma Holdings, Inc. ("China Pharma") which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced the appointment of G. Michael Bennett, Yingwen Zhang and Baowen Dong to its Board of Directors, forming the Company's Audit Committee. G. Michael Bennett is Chairman of the Audit Committee. The Company also announced the resignation of Heung Mei Tsui as a member of the Company's Board of Directors, effective February 1, 2008, with no disagreements The appointment of Bennett, Zhang and Dong to China Pharma's board brings the total number of directors to five, and the total number of independent non-executive directors to three....   more»


China Biopharmaceuticals Holdings »02/05/2008 [Company watch]
China Pharma Holdings, Inc Announces First Quarter 2008 Financial Results

Revenues for the first quarter of 2008 increased approximately 62% to $11.7 million, from $7.2 million in the first quarter of 2007. The significant increase in revenues was due to expanded production of the China Pharma's product portfolio supported by enhanced marketing efforts. The Company believes that this extraordinary growth should provide investors with confidence in China Pharma's ability to execute on their strategic marketing plan going forward. Therefore, the Company is reiterating that its 2008 full- year revenue growth is expected to exceed 40%. Gross profit grew 76% to $5.8 million from $3.3 million in the first quarter of 2007. Gross margins were 49.6% compared to 45.6% recorded during the first quarter of 2008 and 2007 respectively. The growth of gross profit and the improved margins were primarily due to the substantial increase in revenues and the decrease in overall production expenses in the first quarter of 2008. Operating expenses for the three months ended March 31, 2008 decreased 20.7% to $1.2 million compared to the same period in 2007. Selling expenses for the period increased to approximately $0.34 million from 0.15 million in the first quarter of 2007, which is due to the Company's investment in overall marketing. General and administrative expenses were $0.82 million in the three months ended March 31, 2008, a decrease of $0.49 million, or 37.5% compared to the first quarter of 2007, with the improvement emanating from the collection of bad debt reserves written-off in 2007, which reinforces China Pharma's ability to collect customer receivables Operating income for the first quarter of 2008 totalled $4.7 million, a 152.2% increase, compared to $1.8 million for the same period in 2007. Net income was $4.2 million, representing an increase of 76.5% from $2.4 million reported in the same year ago period. Fully diluted earnings per share were $0.11, a 57.1% increase from $0.07 in the first quarter of 2007. "We are pleased to report another quarter of strong revenue and net income growth. The success of our increased marketing efforts and diversified portfolio focusing on therapeutics targeting high mortality and high incidence diseases enabled us to achieve a 62% increase in revenues for the first quarter of 2008," commented Ms. Zhilin Li, President and CEO of China Pharma, "Our ability to prudently manage expenses while collecting on 2007 bad debt reserves contributed to the decrease in operating expenses and resulted in a higher operating margin. We anticipate this trend will continue during 2008 as we aim to maintain or improve margins and profitability going forward."...   more»


China Biopharmaceuticals Holdings »13/05/2008
China Biotics Completes Foundation for Its New Plant

China-Biotics, Inc. a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it completed the foundation work for its new plant at Qing Pu, Shanghai. "The new plant which has a 150 MT capacity is the cornerstone of our growth strategy. We have put over 1,000 pilings in the ground over the last couple of months. We are pleased that the piling work is complete and we have laid a solid foundation on which to build this plant," said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "We have started building the factory infrastructure which we hope to complete by the end of third quarter this year. We have already placed orders for all major equipment that we need." "The new plant has a steel structure and the equipment will also be largely made of steel. With rising Renminbi and steel prices, the construction costs are expected to escalate. Despite this, we believe that our new plant will remain one of the cheapest of its kind," said Mr. Song. "When completed during the 2009 fiscal year, it will be the only large-scale probiotics plant in China that supplies the domestic bulk additive market." About China-Biotics, Inc. Headquartered in Shanghai, China-Biotics, Inc. was founded in 1999 and is one of China's largest suppliers of probiotics. Probiotics are beneficial live bacteria used as dietary supplements and food additives to improve intestinal health and digestion. The Company's product portfolio contains live microbials made with proprietary technology. Currently, these products are sold over-the-counter under the "Shining" brand through large distributors to more than 1,000 pharmacies and 100 supermarkets in Shanghai, Jiangsu and Zhejiang. Shining is one of the most recognized brands in Shanghai. China-Biotics plans to expand its retail sales to other major cities in China and is launching 300 Shining brand logistic centers in these cities. The Company's flagship product, "Shining Essence", has been a profit driver since its launch in April 2001. There is a significant demand for probiotics for use in the bulk additive market, which is currently met by imports. China-Biotics is building a new plant which will increase its production capacity manifolds to capture this market....   more»


China Biopharmaceuticals Holdings »30/05/2008 [Company watch]
China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million

China Pharma Holdings, Inc. ("China Pharma" or "Company") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today announced that it has entered into a Securities Purchase Agreement and a Registration Rights Agreement with institutional and accredited investors ("Investors") pursuant to which China Pharma shall issue and sell five million shares of the Company's common stock at a purchase price of $2.00 per share. The Investors shall also receive three-year warrants to purchase an aggregate of 1.25 million shares of the Company's common stock at an exercise price of $2.80 per share, subject to adjustment. The net proceeds of the offering are expected to be applied to development of new drugs in pipeline, expansion product line and general working capital. Ms. Li, President and CEO of China Pharma said, "We are very pleased to conduct this new financing with high quality institutional investors including several current shareholders. This round of financing will provide us with additional capital to help expedite the development of our new drugs and fund our future growth including the launch of several new drugs and further expansion of our distribution network. We are also quite pleased with the caliber of high quality institutional investors that participated in our private placement. The proceeds raised from our investors reflect continued confidence in our ability to carry out our strategic vision and maximize our shareholders value."...   more»


China Biopharmaceuticals Holdings »15/09/2008 [Company watch]
China Biopharma Effects 1 for 100 Reverse Stock Split

China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that it has filed with the Secretary of State of the State of Delaware an amendment to its Certificate of Incorporation to effect a 1 for 100 reverse stock split. China Biopharma's common stock ("Common Stock") will begin trading on a reverse-split basis on September 15, 2008 under the new symbol CHBO. By unanimous written consent dated July 3, 2008 the Board of Directors adopted an amendment to the Company's Certificate of Incorporation (the "Amendment") to effect a 1 for 100 reverse stock spit of the Company's outstanding Common Stock. The holders of a majority of the outstanding shares of Common Stock by written consent subsequently approved the filing of the Amendment and the reverse split contemplated thereby. As a result of the reverse stock split, each 100 outstanding shares of Common Stock, par value $.0001 per share will be combined into one share of Common Stock; provided, however, that upon such combination, the Corporation shall not issue fractional shares or pay cash in respect thereof, but shall instead issue to each stockholder the aggregate number of shares resulting from the Reverse Stock Split rounded up to the next higher whole number of shares based upon the preceding calculation. The Reverse Split shall have no effect on the number of authorized shares of Common Stock. The reverse stock split affects all shares of common stock, stock options and warrants of China Biopharma outstanding immediately prior to the effective time of the reverse stock split. China Biopharma's Common Stock currently outstanding is approximately 650 million. Stockholders who hold their shares in brokerage accounts or "street name" will not be required to take any action to effect the exchange of their shares. Stockholders of record who hold share certificates will receive a letter of transmittal requesting that they surrender their old stock certificates for new stock certificates reflecting the adjusted number of shares as a result of the reverse stock split. Continental Stock Transfer & Trust Company, China Biopharma's transfer agent, will act as the exchange agent for purposes of implementing the exchange of stock certificates....   more»


China Biopharmaceuticals Holdings »29/12/2008 [Company watch]
China Biopharma achieves significant improvements in 2008

China Biopharma, based at Hangzhou in China announced it had made significant operational improvement after the start of corporate operational restructuring last year....   more»


China Biopharmaceuticals Holdings »22/01/2009 [Company watch]
China Pharma Sees Improvement in Accounts Receivable Collection

China Pharma Holdings released a preliminary snapshot of its 2008 financial results....   more»


China Biopharmaceuticals Holdings »21/01/2009
China Pharma Holdings,today announced a financial preview.

According to the unaudited financial data for the financial year 2008, China Pharma achieved record high revenues....   more»


China Biopharmaceuticals Holdings »19/03/2009 [Company watch]
China Pharma Holdings, Inc.Reports Improved 2008

China Pharma Holdings said its 2008 revenues climbed 54% to $51 million. Net income (excluding foreign exchange) rose 39% to $17.8 million...   more»


China Biopharmaceuticals Holdings »30/04/2009 [Industry news]
China Pharma Holdings, Inc. (CPHI.OB) Appoints Chief Financial Officer and Board Member

China Pharma Holdings, Inc. which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has appointed Mr. Frank Waung to Chief Financial Officer, and has nominated Ms. Heung Mei Tsui to the Board of Directors....   more»


China Biopharmaceuticals Holdings »15/05/2009
China Pharma Holdings, Inc. (CPHI.OB) Reports First Quarter 2009 Financial Results and Corporate Updates

China Pharma Holdings, which develops, manufactures, and markets specialty pharmaceutical products in China, today announced financial results for the first quarter ended March 31, 2009....   more»


China Biopharmaceuticals Holdings »24/06/2009 [Company watch]
China Pharma Wins OK for Generic Cholesterol Drug Trials

China Pharma Holdings (CPHI.OB) obtained approval from the SFDA to begin Phase I and Phase II clinical trials of Rosuvastatin...   more»


China Biopharmaceuticals Holdings »12/08/2009 [Company watch]
China Pharma Holdings, Inc. Reports Second Quarter 2009 Financial Results

China Pharma Holdings, Inc. Reports Second Quarter 2009 Financial Results and Corporate Updates Revenue Increases 20.6% Year Over Year to $13.6 Million...   more»


China Biopharmaceuticals Holdings »18/08/2009 [Company watch]
China Pharma Holdings, Inc. Announces SFDA Approval for Production of Omeprazole Injections

Omeprazole is widely utilized to treat gastroesophageal reflux disease (GERD), and is highly effective in other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison Syndrome....   more»


China Biopharmaceuticals Holdings »12/10/2009 [Company watch]
NeoStem, Inc. Confirms Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company

NeoStem, Inc., which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that the United States Securities and Exchange Commission has declared effective its Registration Statement on Form S-4 filed with the Commission....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.